ARAlonso Gutiérrez Romero

Alonso Gutiérrez Romero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alonso Gutiérrez Romero has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementación del código estado epiléptico en México: tiempo es cerebro

    by Elma Paredes-Aragón, Iris E. Martínez Juárez, Elvira Castro Martínez, Karen E. Guzmán-Sánchez, Mijail Rivas Cruz, Alonso Gutiérrez Romero, Anwar Garcia Santos, Juan Carlos López Hernández

    Introducción: El estado epiléptico es una urgencia neurológica. Se calcula una incidencia de 61 casos por 100,000 habitantes/año. Se estima una mortalidad entre el 20% y el 80%, siendo altamente dependiente de la eficacia y rapidez del manejo, la etiología y los factores de riesgo. Métodos: En esta síntesis narrativa, los autores revisaron la evidencia científica actual y elaboraron una propuesta de expertos para el manejo adaptada para México. Resultados y discusión: Sintetizamos los datos actuales de la evidencia médica para estado epiléptico, con un enfoque practico para la mejora del manejo de los pacientes con estado epiléptico. Conclusión: Los pacientes con estado epiléptico deben tratarse de forma estandarizada para prevenir morbimortalidad y utilizar de forma estandarizada un electroencefalograma continuo.


  • Incidence of Guillain–Barré syndrome following SARS‐CoV‐2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines

    by Miguel García‐Grimshaw, Javier Andrés Galnares‐Olalde, Omar Yaxmehen Bello‐Chavolla, Anaclara Michel‐Chávez, Arturo Cadena‐Fernández, María Eugenia Briseño‐Godínez, Neftali Eduardo Antonio‐Villa, Isaac Núñez, Alonso Gutiérrez‐Romero, Laura Hernández‐Vanegas, et al.

    Background and purpose: Information on Guillain–Barré syndrome (GBS) as an adverse event following immunization (AEFI) against SARS‐CoV‐2 remains scarce. We aimed to report GBS incidence as an AEFI among adult (≥18 years) recipients of 81,842,426 doses of seven anti‐SARS‐CoV‐2 vaccines between December 24, 2020, and October 29, 2021, in Mexico.Methods: Cases were retrospectively collected through passive epidemiological surveillance. The overall observed incidence was calculated according to the total number of administered doses. Vaccines were analyzed individually and by vector as mRNA‐based (mRNA‐1273 and BNT162b2), adenovirus‐vectored (ChAdOx1 nCov‐19, rAd26‐rAd5, Ad5‐nCoV, and Ad26.COV2‐S), and inactivated whole‐virion‐vectored (CoronaVac) vaccines.Results: We identified 97 patients (52 males [53.6%]; median [interquartile range] age 44 [33–60] years), for an overall observed incidence of 1.19/1,000,000 doses (95% confidence interval [CI] 0.97–1.45), with incidence higher among Ad26.COV2‐S (3.86/1,000,000 doses, 95% CI 1.50–9.93) and BNT162b2 recipients (1.92/1,00,000 doses, 95% CI 1.36–2.71). The interval (interquartile range) from vaccination to GBS symptom onset was 10 (3–17) days. Preceding diarrhea was reported in 21 patients (21.6%) and mild COVID‐19 in four more (4.1%). Only 18 patients were tested for Campylobacter jejuni (positive in 16 [88.9%]). Electrophysiological examinations were performed in 76 patients (78.4%; axonal in 46 [60.5%] and demyelinating in 25 [32.8%]); variants were similar across the platforms. On admission, 91.8% had a GBS disability score ≥3. Seventy‐five patients (77.3%) received intravenous immunoglobulin, received seven plasma exchange (7.2%), and 15 (15.5%) were treated conservatively. Ten patients (10.3%) died, and 79.1% of survivors were unable to walk independently.Conclusions: Guillain–Barré syndrome was an extremely infrequent AEFI against SARS‐CoV‐2. The protection provided by these vaccines outweighs the risk of developing GBS.